4 results
1.3. Study Design Rationale The ATLAS-PPX trial (ALN-AT3SC-009) is a multicenter, multinational, open-label Phase 3 switching study designed to demonstrate the efficacy and safety of fitusiran in patients with hemophilia A or B, with inhibitory…
Establishment of a quantitative relationship between NIR measurements and body fluid balance in research subjects exposed to accelerated dehydration by cycling exercise on a home trainer. This explorative study will generate detailed information of…
The ATLAS-A/B trial (ALN-AT3SC-004) is a multicenter, multinational, randomized, openlabel Phase 3 study designed to demonstrate the efficacy and safety of fitusiran in patients with hemophilia A or B without inhibitory antibodies to FVIII or FIX…
The central hypothesis of this study is that dapagliflozin drives a natriuretic effect independently of renal function level. The study will therefore evaluate average 24-hr sodium excretion during dapagliflozin treatment in patients with T2DM with…